Skip to content

US · UPB · BIOTECHNOLOGY

Upstream Bio, Inc. (UPB) intrinsic value and stock valuation

$1.59as of 2026-11-21 · Mkt cap 366.79M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Upstream Bio, Inc. DCF and intrinsic value

InvestorsCraft values UPB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from UPB’s statements →

Upstream Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 upstreambio.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$2.85M
20222025
Net income
-$-143.44M
20222025
Free cash flow
-$-133.28M
20222025
Total equity
$339.8M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$2.85M$2.37M$2.38M$1.21M
Operating income-$-160.36M-$-77.76M-$-40.11M-$-23.91M
Net income-$-143.44M-$-62.81M-$-20.54M-$-23.87M
EPSd-$-2.66M-$-1.22M-$-565.53K-$-657.21K
Operating cash flow-$-133.28M-$-59.17M-$-37.93M-$-19.02M
Capital expenditure-$-170K-$-510K-$-140K-$-80K
Free cash flow-$-133.28M-$-59.68M-$-38.07M-$-19.1M
Total assets$353.8M$481.7M$117.2M$18.5M
Total debt$1.27M$1.83M$40K$90K
Net debt-$-100.31M-$-324.06M-$-25.79M-$-16.96M
Total equity$339.8M$469.9M-$-123.13M-$-106.16M
Cash and short-term investments$341.5M$470.5M$109.8M$17.1M
Income statement
2025202420232022
Revenue$2.85M$2.37M$2.38M$1.21M
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$2.85M$2.37M$2.38M$1.21M
Research and development expenses$136.8M$63M$31.8M$18.7M
Selling, general and administrative expenses$26.4M$17.2M$10.7M$6.46M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$163.2M$80.1M$42.5M$25.1M
Cost and expenses$163.2M$80.1M$42.5M$25.1M
Interest income$16.9M$12.1M$4.17M$200K
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$190K$90K$60K$10K
Ebitda-$-143.25M-$-62.72M-$-20.48M-$-23.86M
Operating income-$-160.36M-$-77.76M-$-40.11M-$-23.91M
Total other income/expenses, net$16.9M$15M$19.6M$40K
Income before tax-$-143.44M-$-62.81M-$-20.54M-$-23.87M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-143.44M-$-62.81M-$-20.54M-$-23.87M
Weighted average shares outstanding$53.9M$51.3M$36.3M$36.3M
Weighted average diluted shares outstanding$53.9M$51.3M$36.3M$36.3M
Balance sheet
2025202420232022
Cash and short-term investments$341.5M$470.5M$109.8M$17.1M
Net receivables$670K$1.18M$240K$410K
Inventory$0.00$0.00$0.00$0.00
Total current assets$351.8M$479.2M$117M$18.3M
Property, plant and equipment, net$1.78M$2.37M$200K$160K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$1.98M$2.56M$200K$170K
Total assets$353.8M$481.7M$117.2M$18.5M
Accounts payable$2.73M$4.04M$1.99M$710K
Short-term debt$720K$700K$40K$90K
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$13.5M$10.7M$6.51M$4.86M
Long-term debt$550K$1.13M$0.00$10K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$550K$1.13M$233.8M$119.8M
Capital lease obligations$0.00$1.83M$40K$90K
Total liabilities$14M$11.9M$240.3M$124.6M
Common stock$50K$50K$0.00$0.00
Retained earnings-$-334.22M-$-190.78M-$-127.97M-$-107.44M
Accumulated other comprehensive income (loss)$530K-$-30K$20K$0.00
Total equity$339.8M$469.9M-$-123.13M-$-106.16M
Total investments$239.9M$144.6M$84M$0.00
Total debt$1.27M$1.83M$40K$90K
Net debt-$-100.31M-$-324.06M-$-25.79M-$-16.96M
Cash flow statement
2025202420232022
Net income-$-143.44M-$-62.81M-$-20.54M-$-23.87M
Depreciation and amortization-$-1.31M$90K$60K$10K
Stock-based compensation$10.3M$6M$3.43M$1.28M
Change in working capital$590K$1.87M-$-4.3M$3.41M
Accounts receivable-$-60K-$-520K$310K-$-410K
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-1.28M$2.02M$1.28M$460K
Net cash provided by operating activities-$-133.28M-$-59.17M-$-37.93M-$-19.02M
Investments in property, plant and equipment-$-170K-$-510K-$-140K-$-80K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-93.48M-$-59.48M-$-82.84M-$-80K
Common stock issued$2.44M$272.7M$129.6M$9.96M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.44M$418.9M$129.6M$9.96M
Net change in cash-$-224.31M$300.3M$8.78M-$-9.14M
Cash at end of period$101.8M$326.1M$25.8M$17.1M
Operating cash flow-$-133.28M-$-59.17M-$-37.93M-$-19.02M
Capital expenditure-$-170K-$-510K-$-140K-$-80K
Free cash flow-$-133.28M-$-59.68M-$-38.07M-$-19.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Upstream Bio, Inc.

        Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

        CEO
        E. Rand Sutherland
        Employees
        75
        Beta
        1.16

        Explore

        Frequently asked questions

        What is the intrinsic value of Upstream Bio, Inc. (UPB)?

        Upstream Bio, Inc. (UPB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is UPB undervalued?

        UPB trades at a price of $1.59 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.